Abeona Therapeutics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Abeona Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed upper quartile by trial count

Abeona Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

Abeona Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epidermolysis Bullosa, with 3 trials.

Upper-quartile sponsor footprint

Abeona Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

NCT05725018
TERMINATED

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

NCT04655911
COMPLETED Phase 3

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106
TERMINATED Phase 1

Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

NCT03315182
COMPLETED Phase 1

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
COMPLETED Phase 2

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

NCT00385502
COMPLETED Phase 3

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563394
COMPLETED Phase 3

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 4

Therapeutic Areas

Epidermolysis Bullosa 3
Recessive Dystrophic Epidermolysis Bullosa 2
RDEB 1
Diabetic Foot Ulcers 1
Epidermolysis Bullosa Dystrophica 1

How the Abeona Therapeutics archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 4 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Epidermolysis Bullosa (3 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Abeona Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Abeona Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Abeona TherapeuticsAB ScienceAbbott Point of CareAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Aciex Therapeutics10xBio22nd Century Group23andMe3-C Institute for Social Development
Abeona Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Abeona Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Abeona Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Abeona Therapeutics or any single study.

  • None of Abeona Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Epidermolysis Bullosa is the condition Abeona Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epidermolysis Bullosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abeona Therapeutics pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.